• Myeloma Clinical Trials
    • Feb 09, 2018

    Clinical Trial: Carfilzomb, Lenalidomide and Dex for Smoldering Myeloma

More treatment options are being considered for high risk smoldering multiple myeloma patients who are likely to progress to active myeloma.  The current standard of care for smoldering myeloma is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for smoldering myeloma itself. One possible treatment involves a combination of cancer treatment drugs.

This study is open at the NIH in Maryland and uses a triple combination also used in multiple myeloma. Lenalidomide is a drug that may help reduce or prevent the growth of cancer cells. Dexamethasone is a steroid that is often given with other anti-cancer drugs. These two drugs are an approved treatment for multiple myeloma that has not responded to at least one other treatment. Carfilzomib is an experimental drug that has been effective in treating multiple myeloma. Researchers want to combine these three drugs to see if they are a safe and effective treatment for SMM.

Learn more about this study on SparkCures:

Smoldering Myeloma Clinical Trial

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$49,561 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: